
## Henry G Burger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4949241/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A prospective population-based study of menopausal symptoms. Obstetrics and Gynecology, 2000, 96, 351-358.	1.2	659
2	Androgen production in women. Fertility and Sterility, 2002, 77, 3-5.	0.5	587
3	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, s1-s66.	1.8	512
4	Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 1995, 21, 227-236.	1.0	488
5	Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment. Fertility and Sterility, 2002, 77, 660-665.	0.5	408
6	Hormonal Changes in the Menopause Transition. Endocrine Reviews, 2002, 57, 257-275.	7.1	382
7	A Prospective Longitudinal Study of Serum Testosterone, Dehydroepiandrosterone Sulfate, and Sex Hormone-Binding Globulin Levels through the Menopause Transition1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2832-2838.	1.8	342
8	Inhibin as a Marker for Granulosa-Cell Tumors. New England Journal of Medicine, 1989, 321, 790-793.	13.9	330
9	Menopausal symptoms in Australian women. Medical Journal of Australia, 1993, 159, 232-236.	0.8	318
10	Prospectively Measured Levels of Serum Follicle-Stimulating Hormone, Estradiol, and the Dimeric Inhibins during the Menopausal Transition in a Population-Based Cohort of Women1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4025-4030.	1.8	314
11	Are changes in sexual functioning during midlife due to aging or menopause?. Fertility and Sterility, 2001, 76, 456-460.	0.5	304
12	Hormones, mood, sexuality, and the menopausal transition. Fertility and Sterility, 2002, 77, 42-48.	0.5	285
13	Elevated Serum Inhibin Concentrations in Postmenopausal Women with Ovarian Tumors. New England Journal of Medicine, 1993, 329, 1539-1542.	13.9	225
14	The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. Fertility and Sterility, 2005, 84, 174-180.	0.5	220
15	Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clinical Endocrinology, 1992, 36, 339-345.	1.2	198
16	Estrogen in Severe Mental Illness. Archives of General Psychiatry, 2008, 65, 955.	13.8	197
17	Sexuality, hormones and the menopausal transition. Maturitas, 1997, 26, 83-93.	1.0	183
18	Cycle and hormone changes during perimenopause. Menopause, 2008, 15, 603-612.	0.8	180

#	Article	IF	CITATIONS
19	Mood and the Menopausal Transition. Journal of Nervous and Mental Disease, 1999, 187, 685-691.	0.5	155
20	Endocrine Features of Menstrual Cycles in Middle and Late Reproductive Age and the Menopausal Transition Classified According to the Staging of Reproductive Aging Workshop (STRAW) Staging System. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3060-3067.	1.8	149
21	Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstetrics and Gynecology, 1996, 88, 437-442.	1.2	142
22	Menopause Transition: Annual Changes in Serum Hormonal Patterns over the Menstrual Cycle in Women during a Nine-Year Period Prior to Menopause. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2763-2769.	1.8	132
23	The endocrinology of the menopause. Maturitas, 1996, 23, 129-136.	1.0	127
24	Follicle-Stimulating Hormone and Somatomedin-C Stimulate Inhibin Production by Rat Granulosa Cells <i>in Vitro</i> *. Endocrinology, 1987, 120, 1633-1638.	1.4	117
25	Modeling women's health during the menopausal transition. Menopause, 2007, 14, 53-62.	0.8	116
26	A Prospective Study of Inhibin in Granulosa Cell Tumors of the Ovary. Gynecologic Oncology, 1994, 55, 285-289.	0.6	107
27	Circulating immunoreactive inhibin and testosterone levels in men with critical illness. Clinical Endocrinology, 1992, 36, 399-404.	1.2	106
28	Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause, 2005, 12, 460-467.	0.8	106
29	The endocrinology of the menopauseProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998 Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 31-35.	1.2	99
30	Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition—an analysis of FSH, oestradiol and inhibin. European Journal of Endocrinology, 1994, 130, 38-42.	1.9	95
31	Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause, 2009, 16, 50-59.	0.8	94
32	The perimenopausal woman: Endocrinology and management. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 121-131.	1.2	94
33	The treatment-seeking woman at menopause. Maturitas, 1994, 18, 161-173.	1.0	88
34	Serum Gonadotropin, Sex Steroid, and Immunoreactive Inhibin Levels in the First Two Years of Life*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 682-686.	1.8	86
35	Decreased Serum Inhibin Levels in Normal Elderly Men: Evidence for a Decline in Sertoli Cell Function with Aging*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 455-459.	1.8	85
36	Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian electrocautery. BJOG: an International Journal of Obstetrics and Gynaecology, 1991, 98, 30-35.	1.1	83

#	Article	IF	CITATIONS
37	A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause, 2009, 16, 509-517.	0.8	82
38	Estrogen Receptor Isoform Gene Expression in Ovarian Stromal and Epithelial Tumors*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1200-1205.	1.8	81
39	Circulating immunoactive inhibin in the luteal phase and early gestation of women undergoing ovulation induction. Fertility and Sterility, 1987, 48, 1001-1005.	0.5	79
40	Relationship of Endogenous Sex Hormones to Lipids and Blood Pressure in Mid-Aged Women. Annals of Epidemiology, 1998, 8, 39-45.	0.9	79
41	Inhibin a-subunit gene expression in the ovaries of immature female rats is stimulated by pregnant mare serum gonadotrophin. Biochemical and Biophysical Research Communications, 1986, 138, 1191-1195.	1.0	78
42	The Menopausal Transition—Endocrinology. Journal of Sexual Medicine, 2008, 5, 2266-2273.	0.3	75
43	Serum Inhibin Concentrations Rise Throughout Normal Male and Female Puberty*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 689-694.	1.8	73
44	Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver. Metabolism: Clinical and Experimental, 1972, 21, 895-904.	1.5	72
45	The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Medical Journal of Australia, 2001, 174, 68-71.	0.8	69
46	Central abdominal fat and endogenous hormones during the menopausal transition. Fertility and Sterility, 2003, 79, 1335-1340.	0.5	66
47	Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?. Schizophrenia Research, 2011, 125, 278-283.	1.1	66
48	No Evidence of a Role for Mutations or Polymorphisms of the Follicle-Stimulating Hormone Receptor in Ovarian Granulosa Cell Tumors <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 274-279.	1.8	62
49	Inhibin forms in serum from postmenopausal women with ovarian cancers. Clinical Endocrinology, 1999, 50, 381-386.	1.2	61
50	New findings from non-linear longitudinal modelling of menopausal hormone changes. Human Reproduction Update, 2007, 13, 551-557.	5.2	56
51	Combined Inhibin and CA125 Assays in the Detection of Ovarian Cancer. Clinical Chemistry, 1999, 45, 651-658.	1.5	55
52	A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles. Menopause, 2008, 15, 1139-1144.	0.8	55
53	Inhibin. Reproductive Medicine Review, 1992, 1, 1-20.	0.3	54
54	Inhibin Subunit Gene Expression in Ovarian Cancer. Gynecologic Oncology, 1999, 73, 273-279.	0.6	52

#	Article	IF	CITATIONS
55	Both Inhibin A and B Respond to Exogenous Follicle-Stimulating Hormone in the Follicular Phase of the Human Menstrual Cycle1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4167-4169.	1.8	49
56	Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause, 2004, 11, 315-322.	0.8	45
57	Nomenclature and endocrinology of menopause and perimenopause. Expert Review of Neurotherapeutics, 2007, 7, S35-S43.	1.4	45
58	Hypericum perforatum with Vitex agnus-castus in menopausal symptoms. Menopause, 2009, 16, 156-163.	0.8	45
59	Metabolic clearance rate of radioiodinated human growth hormone in man. Journal of Clinical Investigation, 1969, 48, 1600-1608.	3.9	45
60	Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2000, 40, 54-58.	0.4	44
61	The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause, 2005, 12, 267-274.	0.8	44
62	Interrelationships between Ovarian and Pituitary Hormones in Ovulatory Menstrual Cycles across Reproductive Age. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 138-144.	1.8	44
63	Sexuality. American Journal of Medicine, 2005, 118, 59-63.	0.6	42
64	Molecular pathogenesis of granulosa cell tumours. Molecular and Cellular Endocrinology, 2002, 191, 89-96.	1.6	39
65	5Inhibin—a non-steroidal regulator of pituitary follicle stimulating hormone. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 89-112.	1.0	38
66	Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas, 2012, 73, 127-133.	1.0	37
67	Stimulation of Serum Inhibin Concentrations by Gonadotropin-Releasing Hormone in Men With Idiopathic Hypogonadotropic Hypogonadism*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 1221-1224.	1.8	36
68	Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1395-1401.	1.8	36
69	Testosterone and Libido in Surgically and Naturally Menopausal Women. Women's Health, 2006, 2, 459-477.	0.7	35
70	An Inverse Relationship Exists between Seminal Plasma Inhibin and Serum Follicle-Stimulating Hormone in Man*. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 796-803.	1.8	34
71	Inhibins and activins: clinical advances in reproductive medicine. Clinical Endocrinology, 2003, 58, 115-127.	1.2	34
72	The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporosis International, 2004, 15, 881-886.	1.3	33

#	Article	IF	CITATIONS
73	Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Table 1. Journal of Family Planning and Reproductive Health Care, 2012, 38, 102-109.	0.9	33
74	Effects of a Combination of <i>Hypericum perforatum</i> and <i>Vitex agnus-castus</i> on PMS-Like Symptoms in Late-Perimenopausal Women: Findings from a Subpopulation Analysis. Journal of Alternative and Complementary Medicine, 2009, 15, 1045-1048.	2.1	32
75	<i>Vitex agnus-castus</i> (Chaste-Tree/Berry) in the Treatment of Menopause-Related Complaints. Journal of Alternative and Complementary Medicine, 2009, 15, 853-862.	2.1	32
76	Direct inhibition of rat granulosa cell inhibin production by epidermal growth factor in vitro. Molecular and Cellular Endocrinology, 1987, 54, 213-220.	1.6	31
77	Pregnant Mare's Serum Conadotropin Stimulates Inhibin Subunit Gene Expression in the Immature Rat Ovary: Dose Response Characteristics and Relationships to Serum Gonadotropins, Inhibin, and Ovarian Steroid Content*. Endocrinology, 1988, 123, 2399-2407.	1.4	31
78	Ovarian sensitization to gonadotrophins by human growth hormone. Persistence of the effect beyond the treated cycle. Clinical Endocrinology, 1991, 35, 119-122.	1.2	30
79	Physiological Principles of Endocrine Replacement: Estrogen. Hormone Research in Paediatrics, 2001, 56, 82-85.	0.8	29
80	Reproductive hormones: ageing and the perimenopause. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 612-616.	1.3	29
81	A clinical update on female androgen insufficiency—testosterone testing and treatment in women presenting with low sexual desire. Sexual Health, 2006, 3, 73.	0.4	27
82	Inhibins and ovarian cancer. Molecular and Cellular Endocrinology, 2004, 225, 65-71.	1.6	26
83	Changes in serum antimüllerian hormone levels across the ovulatory menstrual cycle in late reproductive age. Menopause, 2011, 18, 521-524.	0.8	26
84	Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies. Journal of Family Planning and Reproductive Health Care, 2013, 39, 80-88.	0.9	25
85	Sertoli-Leydig Cell Tumor of the Ovary, a Rare Cause of Precocious Puberty in a 12-Month-Old Infant. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 49-56.	1.8	24
86	Competency in Menopause Management: Whither Goest the Internist?. Journal of Women's Health, 2014, 23, 281-285.	1.5	24
87	Genomic Basis of Aromatase Excess Syndrome: Recombination- and Replication-Mediated Rearrangements Leading to CYP19A1 Overexpression. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E2013-E2021.	1.8	23
88	Editorial: Inhibin in the Male—Progress at Last*. Endocrinology, 1997, 138, 1361-1362.	1.4	22
89	The rationale for physiological testosterone replacement in women. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 391-405.	1.0	22
90	A Prospective Population-Based Study of Menopausal Symptoms. Obstetrics and Gynecology, 2000, 96, 351-358.	1.2	22

#	Article	IF	CITATIONS
91	The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric, 2007, 10, 267-269.	1.1	22
92	Inhibin and age in men. Clinical Endocrinology, 1991, 35, 341-346.	1.2	21
93	Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial. BMC Medical Research Methodology, 2009, 9, 41.	1.4	21
94	Isolation of inhibin from ovine follicular fluid using reversed-phase liquid chromatography. Molecular and Cellular Endocrinology, 1983, 31, 187-198.	1.6	20
95	Cloning and characterization of the rat α-inhibin gene. Molecular and Cellular Endocrinology, 1990, 68, 121-128.	1.6	20
96	Physiology and endocrinology of the menopause. Medicine, 2006, 34, 27-30.	0.2	20
97	Associations Between Antral Ovarian Follicle Dynamics and Hormone Production Throughout the Menstrual Cycle as Women Age. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4553-4562.	1.8	20
98	Hypothesis: Placental membranes produce prolactin. Molecular and Cellular Endocrinology, 1978, 11, 1-6.	1.6	18
99	The role of androgen therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 165-175.	2.2	18
100	The specificity of inhibin bioassay using cultured pituitary cells. Molecular and Cellular Endocrinology, 1982, 27, 307-316.	1.6	17
101	The Ageing Female Reproductive Axis I. Novartis Foundation Symposium, 2008, , 161-171.	1.2	17
102	Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. Menopause, 2009, 16, 792-796.	0.8	17
103	Hormone therapy in the WHI era. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 84-91.	0.4	15
104	Mammographic densities during the menopausal transition. Menopause, 2007, 14, 208-215.	0.8	15
105	Unpredictable endocrinology of the menopause transition: clinical, diagnostic and management implications. Menopause International, 2011, 17, 153-154.	1.6	15
106	A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®. Contraception, 2011, 84, 600-608.	0.8	15
107	The Menopause: When It Is All Over or Is It?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1994, 34, 293-295.	0.4	14
108	The Y Chromosome and Spermatogenesis. New England Journal of Medicine, 1997, 336, 576-578.	13.9	14

#	Article	IF	CITATIONS
109	Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric, 2004, 7, 210-216.	1.1	14
110	Effect of Synthetic Thyrotrophin Releasing Hormone (TRH) in Man. Australian and New Zealand Journal of Medicine, 1972, 2, 366-375.	0.5	13
111	The inhibin/activin family and ovarian cancer. Trends in Endocrinology and Metabolism, 1996, 7, 197-202.	3.1	13
112	Inhibin and reproductive aging. Experimental Gerontology, 2000, 35, 33-39.	1.2	12
113	THE VALUE OF SERUM THYROTROPHIN MEASUREMENT IN THE DIAGNOSIS AND MANAGEMENT OF HYPOTHYROIDISM. Medical Journal of Australia, 1972, 2, 293-297.	0.8	11
114	Response of serum inhibin B and pro-alphaC levels to gonadotrophic stimulation in normal men before and after steroidal contraceptive treatment. Human Reproduction, 2003, 18, 734-743.	0.4	10
115	Perimenopausal Reproductive Endocrinology. Endocrinology and Metabolism Clinics of North America, 2005, 34, 907-922.	1.2	10
116	Editorial: Inhibin in the Male—Progress at Last. , 0, .		10
117	Induction of ovulation with gonadotrophinâ€releasing hormone — lifeâ€table analysis of 50 courses of treatment. Medical Journal of Australia, 1989, 151, 21-26.	0.8	10
118	Inhibin as a tumour marker. Clinical Endocrinology, 1994, 41, 151-153.	1.2	9
119	The role of androgen therapy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 383-393.	1.4	9
120	Elevated Serum Inhibin and Tumor-Associated Trypsin Inhibitor Concentrations in a Young Woman with Dysgerminoma of the Ovary. Gynecologic Oncology, 1998, 71, 465-468.	0.6	8
121	WHI risks: Any relevance to menopause management?. Maturitas, 2007, 57, 6-10.	1.0	7
122	Human chorionic gonadotrophin-induced suppression of serum inhibin involves reduction in ovarian inhibin α-subunit messenger RNA levels in the pregnant mare serum gonadotrophin-primed female rat. Molecular and Cellular Endocrinology, 1989, 61, 123-128.	1.6	6
123	Hormone therapy use in Australianâ€born women: a longitudinal study. Medical Journal of Australia, 1999, 171, 358-361.	0.8	6
124	The ageing female reproductive axis I. Novartis Foundation Symposium, 2002, 242, 161-7; discussion 167-71.	1.2	6
125	Inhibin: Circulating Levels in Women during Ovulation Induction and Detection in Human Placenta by Specific Radioimmunoassay. Annals of the New York Academy of Sciences, 1988, 541, 162-178.	1.8	5
126	What Do Inhibin Measurements Tell A Clinician Today?. Annals of Medicine, 1992, 24, 419-421.	1.5	5

#	Article	IF	CITATIONS
127	The AHA guidelines on hormone replacement therapy and cardiovascular disease. Maturitas, 2001, 40, 1-3.	1.0	5
128	Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. Expert Review of Neurotherapeutics, 2007, 7, S115-S137.	1.4	5
129	Effects of FSH on serum immunoreactive inhibin levels in the luteal phase of the menstrual cycle. Clinical Endocrinology, 1996, 45, 431-434.	1.2	4
130	Should women be treated with testosterone?. Clinical Endocrinology, 1998, 49, 159-160.	1.2	4
131	Should testosterone be added to estrogen-progestin therapy for breast protection?. Menopause, 2007, 14, 159-162.	0.8	4
132	RE: Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study. Journal of the National Cancer Institute, 2014, 106, djt372-djt372.	3.0	3
133	Prognosis of pregnancies conceived by donor insemination with respect to the late follicular phase luteinizing hormone levels. BJOC: an International Journal of Obstetrics and Gynaecology, 1990, 97, 654-656.	1.1	2
134	Chapter 17 Infertility. Principles of Medical Biology, 1998, , 317-332.	0.1	2
135	How effective is testosterone replacement therapy in premenopausal women with severe androgen deficiency?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 432-433.	2.9	2
136	Biological and Psychosocial Factors Affecting Sexual Functioning During the Menopausal Transition. , 2000, , 211-222.		2
137	Letter to the editor. Contraception, 1986, 33, 421-422.	0.8	1
138	Menopause and Hormone Replacement Therapy. , 2004, , 795-817.		1
139	Clinical Evaluation of Women Presenting with Low Libido and Determination of Whether Androgen Therapy Might Be Appropriate. Seminars in Reproductive Medicine, 2006, 24, 086-096.	0.5	1
140	Endocrine Changes During the Perimenopause. , 2007, , 67-76.		1
141	Gonadal Peptides. , 2016, , 2037-2050.e6.		1
142	Androgen Replacement in Women. , 1999, , 401-417.		1
143	ADVANCES IN REPRODUCTIVE MEDICINE: AUSTRALIAN CONTRIBUTIONS. Australian and New Zealand Journal of Medicine, 1988, 18, 263-277.	0.5	0
144	Hormone replacement therapy and breast cancer. Medical Journal of Australia, 1998, 169, 399-399.	0.8	0

#	Article	IF	CITATIONS
145	Osteoporosis prevention and treatment. Medical Journal of Australia, 2000, 173, 167-167.	0.8	Ο
146	Raloxifene reduced the risk of cardiovascular events in women with osteoporosis and high cardiovascular risk. Evidence-Based Obstetrics and Gynecology, 2002, 4, 156-157.	0.3	0
147	Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings: authors' response. Journal of Family Planning and Reproductive Health Care, 2013, 39, 228-229.	0.9	0
148	Physiology and Endocrinology of the Menopause. Medicine, 2001, 29, 1-6.	0.2	0
149	Sexuality, Midlife, and Menopause. Medical Science Symposia Series, 2002, , 361-371.	0.0	Ο
150	Gonadal Peptides. , 2010, , 2118-2133.		0
151	Production of Inhibin-Related Peptides by Ovarian Tumors. , 1997, , 162-169.		0
152	Pituitary dysfunction in recently post-menopausal women. Clinical Endocrinology, 1998, 48, 124-124.	1.2	0